<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924404</url>
  </required_header>
  <id_info>
    <org_study_id>200903757</org_study_id>
    <nct_id>NCT00924404</nct_id>
  </id_info>
  <brief_title>Xylitol Versus Saline in Chronic Sinusitis</brief_title>
  <official_title>Randomized Controlled Trial of Xylitol Versus Saline Rinse For Chronic Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is a xylitol nasal rinse better or worse than saline on patient satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot study, the investigators plan to compare the efficacy of twice daily xylitol
      nasal rinse with saline rinse which is the current standard, on outcomes such as quality of
      life and exacerbations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNOT-20 Scores at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sinonasal outcome test is a 20 item quality of life questionnaire: Min-Max score range 0-100 The SNOT score for each patient was defined as the mean value of the response to the 20 items. The questionnaire is divided into 4 subsets, symptoms related to nose, symptoms of ear and face, sleep quality and psychological issues.
Symptoms arereported on 100 mm visual analog scales (VASs) where 0 mm represents no symptoms and 100 mm represent &quot;as troublesome as possible&quot;. The symptom severity is considered mild between 0 and 30, moderate from 30 to 70 and severe from 70- 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Courses</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean Number of antibiotic courses for infections during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Chronic Sinusitis</condition>
  <arm_group>
    <arm_group_label>Xylitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>isotonic xylitol for sinus rinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>saline for sinus rinse</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <description>5% solution for sinus rinse</description>
    <arm_group_label>Xylitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>saline for sinus rinse</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Salt solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        We now have two arms to this study.

        Group I: Immunocompetent subjects with chronic rhinosinusitis

        Inclusion Criteria:

          -  56 Adult subjects (18 or older) presenting to the ENT(ears, nose, throat) clinics who
             meet the diagnosis of chronic rhinosinusitis (CRS). Definition of CRS: Presence of at
             least 2 of the following 4 signs/symptoms for 12 weeks or longer despite medical
             management:

               -  Anterior and/or posterior mucopurulent drainage

               -  Nasal obstruction

               -  Facial pain, pressure, and/or fullness

               -  Decreased sense of smell

          -  In addition, objective evidence of sinus mucosal disease must be demonstrated on sinus
             CT imaging or direct endoscopic examination.

        Exclusion Criteria:

          -  Cystic fibrosis

          -  Fungal sinusitis

          -  Immunocompromised status (use of long term oral steroids (&gt; 30 days), AIDS, active
             malignancy or chemotherapy)

          -  Known Ciliary disorders

          -  Sinonasal tumors

          -  Pregnancy

        Group 2: CRS with antibody deficiency

          -  56 Adult subjects (18 or older) presenting to the Allergy clinic who meet the
             diagnosis of chronic rhinosinusitis (CRS). Definition of CRS: Presence of at least 2
             of the following 4 signs/symptoms for 12 weeks or longer despite medical management:

               -  Anterior and/or posterior mucopurulent drainage

               -  Nasal obstruction

               -  Facial pain, pressure, and/or fullness

               -  Decreased sense of smell

          -  In addition, objective evidence of sinus mucosal disease must be demonstrated on sinus
             CT imaging or direct endoscopic examination.

        Exclusion criteria:

        Cystic Fibrosis Sinonasal tumors Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmi Durairaj, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2009</study_first_posted>
  <results_first_submitted>May 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2017</results_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Lakshmi Durairaj</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Xylitol vs. Saline</keyword>
  <keyword>nasal washes</keyword>
  <keyword>sinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xylitol</title>
          <description>isotonic xylitol for sinus rinse
Xylitol: 5% solution for sinus rinse</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>saline for sinus rinse
Saline: saline for sinus rinse</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xylitol</title>
          <description>isotonic xylitol for sinus rinse
Xylitol: 5% solution for sinus rinse</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>saline for sinus rinse
Saline: saline for sinus rinse</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="14"/>
                    <measurement group_id="B2" value="55" spread="17"/>
                    <measurement group_id="B3" value="54" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SNOT-20 Scores at 12 Weeks</title>
        <description>Sinonasal outcome test is a 20 item quality of life questionnaire: Min-Max score range 0-100 The SNOT score for each patient was defined as the mean value of the response to the 20 items. The questionnaire is divided into 4 subsets, symptoms related to nose, symptoms of ear and face, sleep quality and psychological issues.
Symptoms arereported on 100 mm visual analog scales (VASs) where 0 mm represents no symptoms and 100 mm represent “as troublesome as possible”. The symptom severity is considered mild between 0 and 30, moderate from 30 to 70 and severe from 70- 100.</description>
        <time_frame>12 weeks</time_frame>
        <population>We initially enrolled 53 subjects but we had 10 subjects drop out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Xylitol</title>
            <description>isotonic xylitol for sinus rinse
Xylitol: 5% solution for sinus rinse</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>saline for sinus rinse
Saline: saline for sinus rinse</description>
          </group>
        </group_list>
        <measure>
          <title>SNOT-20 Scores at 12 Weeks</title>
          <description>Sinonasal outcome test is a 20 item quality of life questionnaire: Min-Max score range 0-100 The SNOT score for each patient was defined as the mean value of the response to the 20 items. The questionnaire is divided into 4 subsets, symptoms related to nose, symptoms of ear and face, sleep quality and psychological issues.
Symptoms arereported on 100 mm visual analog scales (VASs) where 0 mm represents no symptoms and 100 mm represent “as troublesome as possible”. The symptom severity is considered mild between 0 and 30, moderate from 30 to 70 and severe from 70- 100.</description>
          <population>We initially enrolled 53 subjects but we had 10 subjects drop out of the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="15"/>
                    <measurement group_id="O2" value="11" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Courses</title>
        <description>Mean Number of antibiotic courses for infections during the study period</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Xylitol</title>
            <description>isotonic xylitol for sinus rinse
Xylitol: 5% solution for sinus rinse</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>saline for sinus rinse
Saline: saline for sinus rinse</description>
          </group>
        </group_list>
        <measure>
          <title>Courses</title>
          <description>Mean Number of antibiotic courses for infections during the study period</description>
          <units>antibiotic courses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.30"/>
                    <measurement group_id="O2" value="1.77" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Xylitol</title>
          <description>isotonic xylitol for sinus rinse
Xylitol: 5% solution for sinus rinse</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>saline for sinus rinse
Saline: saline for sinus rinse</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lakshmi Durairaj</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-353-7968</phone>
      <email>lakshmi-durairaj@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

